In a report released today, Michael Matson from Needham reiterated a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $48.00. The company’s shares closed last Wednesday at $36.28, close to its 52-week low of $35.09.
According to TipRanks.com, Matson is a 3-star analyst with an average return of 1.1% and a 43.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $49.67.
Boston Scientific’s market cap is currently $50.28B and has a P/E ratio of 67.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
Read More on BSX: